Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

TitleLong-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Publication TypeJournal Article
Year of Publication2009
AuthorsSallee, FR, Lyne A, Wigal T, McGough JJ
JournalJournal of child and adolescent psychopharmacology
Volume19
Issue3
Pagination215-26
Date Published2009 Jun
ISSN1557-8992
KeywordsAdolescent, Adrenergic alpha-Agonists, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Guanfacine, Humans, Male, Treatment Outcome
Abstract

Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR.

DOI10.1016/j.comppsych.2011.05.003
Alternate JournalJ Child Adolesc Psychopharmacol